Ask AI
ProCE Banner Activity

CE / CME

Moving the Needle: Leveraging Emerging Strategies for Better Endometrial Cancer Care

Video

In this certified on-demand webcast, experts discuss the evolving treatment landscape for advanced and recurrent endometrial cancer, including molecular classification, guideline-based first-line chemoimmunotherapy, targeted options, and strategies for second-line care. They also explore emerging antibody–drug conjugates and other novel approaches and provide practical considerations for toxicity management and improving equitable access to clinical trials.

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 08, 2025

Expiration: June 07, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from Eisai, Gilead Sciences, Inc., and Merck Sharp & Dohme LLC.

Eisai

Gilead Sciences, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This educational activity is intended for medical oncologists and other healthcare professionals who care for patients with endometrial cancer.

Program Learning Goal

This activity aims to improve learners' knowledge, confidence, and competence at integrating novel therapies into the care of patients with advanced endometrial cancer progressing after standard frontline immunotherapy plus chemotherapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze current recommendations for molecular testing in endometrial cancer, including the rationale, patient counseling approaches, optimal test ordering strategies, and clinical implications of key biomarkers

  • Compare and contrast the efficacy, safety, and appropriate patient selection criteria for available and emerging immune checkpoint inhibitor–based and targeted therapies in endometrial cancer management

  • Analyze the latest clinical data on emerging antibody–drug conjugates (ADCs) for advanced endometrial cancer, examining their mechanisms of action, efficacy, safety profiles, and potential impact on treatment strategies

  • Examine key factors contributing to care disparities in endometrial cancer patients, with a focus on Black, transgender, and underserved populations, and critically evaluate strategies to address these disparities in clinical practice

Disclosure

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Nicoletta Colombo, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, BioNTech, Eisai, Genmab, Gilead, GSK, ImmunoGen, Lilly, MSD, Nuvation Bio, OncXerna, Regeneron, Seagen.

Domenica Lorusso, MD, PhD, Prof: consultant/advisor/speaker: AbbVie, AstraZeneca, Corcept, Daiichi Sankyo, Genentech, Genmab, GSK, Merck Sharp & Dohme, Sutro; researcher: AstraZeneca, Clovis Oncology, Corcept, Genmab, GSK, ImmunoGen, Incyte, Merck Sharp & Dohme, Novartis, PharmaMar, Roche, Seagen.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 08, 2025, through June 07, 2026:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Clinical Care Options, LLC dba Decera Clinical Education's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC dba Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.